What is Recipharm?
Established in 1995, Recipharm operates as a vital link in the pharmaceutical value chain, providing comprehensive contract development and manufacturing services. The organization specializes in managing the entire product lifecycle, from initial formulation and early-stage development to large-scale commercial manufacturing. By maintaining high-quality standards and technical expertise, Recipharm serves as an essential outsourced partner for companies looking to optimize their drug development timelines and manufacturing efficiency. Its market position is defined by its ability to handle diverse therapeutic areas and complex delivery systems, making it a cornerstone of the European pharmaceutical manufacturing landscape.
How much funding has Recipharm raised?
Recipharm has raised a total of $612.4M across 8 funding rounds:
Share Placement
$20M
Debt
$101.3M
Stock Offering
$87M
Debt
$160.2M
Stock Offering
$29.5M
Debt
$106.8M
Stock Offering
$54.2M
Stock Offering
$53.4M
Share Placement (2011): $20M with participation from Nordea Funds
Debt (2012): $101.3M led by Swedbank AB
Stock Issuance/Offering (2014): $87M supported by Undisclosed
Debt (2014): $160.2M featuring Handelsbanken, DNB, and Swedbank
Stock Issuance/Offering (2016): $29.5M backed by Undisclosed
Debt (2016): $106.8M with participation from Undisclosed
Stock Issuance/Offering (2018): $54.2M led by Undisclosed
Stock Issuance/Offering (2020): $53.4M supported by Gladiator, Lansforsakringar, and Polar Capital
Key Investors in Recipharm
Gladiator
An investment firm focused on identifying high-growth opportunities within the European market, often participating in strategic equity rounds.
Lansforsakringar
A major Swedish insurance and banking group that provides institutional capital to support long-term corporate development and industrial growth.
Polar Capital
A specialized investment management firm known for its focus on sector-specific growth and providing capital to companies with strong market fundamentals.
What's next for Recipharm?
Looking ahead, Recipharm is well-positioned to leverage its recent capital influx to further integrate advanced manufacturing technologies and expand its global reach. As the pharmaceutical industry faces increasing pressure to accelerate time-to-market for new therapies, the company's focus on operational excellence and capacity expansion will be paramount. The strategic deployment of these funds is expected to bolster its competitive advantage, allowing for potential acquisitions or facility upgrades that align with the evolving needs of its international client base. By maintaining a robust balance sheet, Recipharm is prepared to navigate future market volatility while continuing to provide high-value services to the global healthcare sector.
See full Recipharm company page
